The anti-diabetic activity of Bifidobacterium lactis HY8101 in vitro and in vivo.

Kim, S-H; Huh, C-S; Choi, I-D; Jeong, J-W; Ku, H-K; Ra, J-H; Kim, T-Y; Kim, G-B; Sim, J-H; Ahn, Y-T

Kim, S-H; Huh, C-S; Choi, I-D; Jeong, J-W; Ku, H-K; Ra, J-H; Kim, T-Y; Kim, G-B; Sim, J-H; Ahn, Y-T.

Affiliation

Kim SH; R&BD Center, Korea Yakult Co. Ltd., Yongin, Korea.

J Appl Microbiol ; 117(3): 834-45, 2014 Sep.

Article in En | MEDLINE | ID: mdl-24925305

Subject(s)

Bifidobacterium; Diabetes Mellitus, Type 2/therapy; Insulin Resistance; Probiotics/therapeutic use; Animals; Blood Glucose/analysis; Cell Line; Diabetes Mellitus, Type 2/blood; Diabetes Mellitus, Type 2/metabolism; Glucose/metabolism; Glucose Transporter Type 4/metabolism; Glycogen/metabolism; Insulin/pharmacology; Insulin Receptor Substrate Proteins/metabolism; Liver/metabolism; Male; Mice; Mice, Inbred C57BL; Muscle, Skeletal/metabolism; Rats; Signal Transduction; Tumor Necrosis Factor-alpha/pharmacology

Key words

AKT; GLUT4; IRS-1; KK-AY mice; Rat L6 skeletal muscle cells; TNF-α; glucose uptake; insulin resistance

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bifidobacterium / Insulin Resistance / Probiotics / Diabetes Mellitus, Type 2 Type of study: Prognostic_studies Limits: Animals Language: En Journal: J Appl Microbiol Year: 2014 Document type: Article

Fulltext

XML

PubMed Links

Search on Google